CONSORTIUM-IO was the first-in-human multicenter, open-label study; the main objectives were to evaluate:
* Safety and tolerability of VE800 in combination with nivolumab
* Efficacy as measured by objective response rate
The study planned to enroll approximately 111 patients with melanoma, gastric/gastroesophageal junction (GEJ) adenocarcinoma, or microsatellite-stable (MSS) colorectal cancer (CRC).
Nivolumab is already approved by the U.S. Food and Drug Administration (FDA), however, it is not approved for the study cancer indications. VE800 was the investigational product, which was designed to enhance the immune response to the tumor.
